A 10-Gene Signature to Predict the Prognosis of Early-Stage Triple-Negative Breast Cancer
Cancer Research and Treatment · 2024
DOI: 10.4143/crt.2024.100 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Research and Treatment, 2024. Verfasst von Chang Min Kim und 13 weiteren Autor:innen. Beteiligte Einrichtung: CbsBioscience. Inc., Daejeon, Korea. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Biomarkers, Tumor, Gene Expression Profiling. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: NIEHS NIH HHS, Ministry of Health and Welfare, Korea Health Industry Development Institute.
Abstract (Originalsprache)
Purpose
Triple-negative breast cancer (TNBC) is a particularly challenging subtype of breast cancer, with a poorer prognosis compared to other subtypes. Unfortunately, unlike luminal-type cancers, there is no validated biomarker to predict the prognosis of patients with early-stage TNBC. Accurate biomarkers are needed to establish effective therapeutic strategies.Materials and Methods In this study, we analyzed gene expression profiles of tumor samples from 184 TNBC patients (training cohort, n=76; validation cohort, n=108) using RNA sequencing.
Results
By combining weighted gene expression, we identified a 10-gene signature (DGKH, GADD45B, KLF7, LYST, NR6A1, PYCARD, ROBO1, SLC22A20P, SLC24A3, and SLC45A4) that stratified patients by risk score with high sensitivity (92.31%), specificity (92.06%), and accuracy (92.11%) for invasive disease-free survival. The 10-gene signature was validated in a separate institution cohort and supported by meta-analysis for biological relevance to well-known driving pathways in TNBC. Furthermore, the 10-gene signature was the only independent factor for invasive disease-free survival in multivariate analysis when compared to other potential biomarkers of TNBC molecular subtypes and T-cell receptor β diversity. 10-gene signature also further categorized patients classified as molecular subtypes according to risk scores.
Conclusion
Our novel findings may help address the prognostic challenges in TNBC and the 10-gene signature could serve as a novel biomarker for risk-based patient care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CbsBioscience. Inc., Daejeon, Korea.
- Department of Pharmacy, College of Pharmacy, CHA University, Seongnam, Korea.
- Division of Medical Oncology/Hematology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
- Samsung Genome Institute, Samsung Medical Center, Seoul, Korea.
- Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- Breast Cancer Center, National Cancer Center, Goyang, Korea.
Förderung
- NIEHS NIH HHS
- Ministry of Health and Welfare
- Korea Health Industry Development Institute
- National Cancer Center
Zitieren
APA
Kim, C. M., Park, K. H., Yu, Y. S., Kim, J. W., Park, J. Y., Park, K., Yu, J. H., Lee, J. E., Sim, S. H., Seo, B. K., Kim, J. K., Lee, E. S., Park, Y. H., & Kong, S. Y. (2024). A 10-Gene Signature to Predict the Prognosis of Early-Stage Triple-Negative Breast Cancer. Cancer Research and Treatment. https://doi.org/10.4143/crt.2024.100
Vancouver
Kim CM, Park KH, Yu YS, Kim JW, Park JY, Park K, et al. A 10-Gene Signature to Predict the Prognosis of Early-Stage Triple-Negative Breast Cancer. Cancer Research and Treatment. 2024. doi:10.4143/crt.2024.100
BibTeX
@article{Kim2024,
author = {Kim, Chang Min and Park, Kyong Hwa and Yu, Yun Suk and Kim, Ju Won and Park, Jin Young and Park, Kyunghee and Yu, Jong-Han and Lee, Jeong Eon and Sim, Sung Hoon and Seo, Bo Kyoung and Kim, Jin Kyeoung and Lee, Eun Sook and Park, Yeon Hee and Kong, Sun-Young},
title = {A 10-Gene Signature to Predict the Prognosis of Early-Stage Triple-Negative Breast Cancer},
journal = {Cancer Research and Treatment},
year = {2024},
doi = {10.4143/crt.2024.100}
}
EUVIMED